Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
This research study is investigating a new treatment approach for extrahepatic cholangiocarcinoma, a type of bile duct cancer that affects ducts outside the liver and cannot be removed by surgery. The study combines a local heating treatment called intraductal radiofrequency ablation (ID-RFA), which helps clear the bile ducts, with standard chemotherapy (Gemcitabine and Cisplatin) and a new immunotherapy drug called Durvalumab. Researchers want to see if adding RFA to the chemotherapy and Durvalumab might be more effective at fighting the cancer than current treatments. This trial is in its second phase, meaning it's still an early study, and will involve patients who have already had RFA and stenting to relieve bile duct blockages. The goal is to improve anti-cancer activity for these patients.
En un coup d'œil
De quoi parle cette étude ?
This study is about an important type of cancer found in the bile ducts outside the liver, called extrahepatic cholangiocarcinoma. For some people, this cancer can't be completely removed with surgery. In these cases, doctors look for other ways to treat it and slow its growth.
This study will combine a few different treatments that are already used. First, there's a procedure called intraductal radiofrequency ablation, or ID-RFA. This uses heat directly inside the bile ducts to destroy cancer cells and help keep the ducts open. Patients taking part in this study will have already had this treatment and a stent placed to help with any blockages. After that, they will receive standard chemotherapy drugs called Gemcitabine and Cisplatin. On top of this, they'll also get a newer medicine called Durvalumab, which is a type of immunotherapy that helps your body's immune system fight cancer.
The main idea behind this research is to see if putting all these treatments together – ID-RFA, chemotherapy, and Durvalumab – works better at fighting the cancer than just using chemotherapy alone. Doctors are hoping this combination will be more powerful against the cancer cells. This is a Phase 2 study, which means it's an early stage of research to check if the treatment is safe and shows promising results in a group of patients.
Points clés
- Targets bile duct cancer outside the liver that can't be surgically removed.
- Combines local heat treatment (RFA) with chemotherapy and immunotherapy (Durvalumab).
- Aims to improve cancer fighting ability for this specific patient group.
- It's a Phase 2 study, meaning it's an early look at safety and effectiveness.
- Patients will have already had RFA for bile duct blockages.
Qui peut être éligible ?
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of extrahepatic cholangiocarcinoma that affects the bile ducts outside the liver and cannot be removed by surgery. Also, you must have already had an RFA procedure and a stent placed to help with any bile duct blockages, and these blockages should now be resolved.
Your medical team needs to agree that standard chemotherapy is suitable for you, and you should be healthy enough for it, apart from any temporary issues caused by bile duct blockages. Generally, you should be able to look after yourself with minimal help, have a life expectancy of at least 12 weeks, and weigh more than 30 kg (about 4 stone 10 pounds). Your blood tests for your blood count, liver, and kidney function also need to be within a certain healthy range.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous au moins 18 ans ?
- Do you have extrahepatic cholangiocarcinoma that can't be removed by surgery?
- Have you already had RFA and a stent placed for bile duct blockages, and are they now clear?
- Are you generally well enough for chemotherapy?
- Do you have a life expectancy of at least 12 weeks?
En quoi consiste la participation ?
If you decide to take part in this study, you will be given a combination of treatments. This includes specific chemotherapy drugs, Gemcitabine and Cisplatin, along with the drug Durvalumab. You will also be eligible for repeat RFA procedures during the study if your doctor decides it's needed.
Participation will involve regular hospital visits for treatments, check-ups, and tests to monitor your health and how you're responding to the treatment. This will include blood tests, scans, and physical examinations. The exact schedule will be explained by the study team, but it will continue for as long as the treatment is benefiting you and you are tolerating it well. Following study rules, attending all scheduled appointments, and undergoing specific examinations are important parts of your commitment.
Risques et avantages potentiels
Emplacements (10)
- Uniklinik RWTH AachenCode postal vérifiéAix-la-Chapelle, Allemagne· Recrutement
- Universitätsklinikum BonnCode postal vérifiéBonn, Germany· Recrutement
- Universitätsklinikum KölnCode postal vérifiéCologne, Allemagne· Recrutement
- Universitätsklinikum DüsseldorfCode postal vérifiéDüsseldorf, Allemagne· Recrutement
- Hôpital Nord-OuestCode postal vérifiéFrancfort, Allemagne· Recrutement
- Universitätsmedizin GöttingenCode postal vérifiéGöttingen, Allemagne· Recrutement
- Medizinische Hochschule HannoverCode postal vérifiéHanover, Germany· Recrutement
- UKSH Campus LübeckCode postal vérifiéLübeck, Allemagne· Recrutement
- Universitaetsmedizin der Johannes Gutenberg-Universitaet MainzCode postal vérifiéMainz, Allemagne· Recrutement
- Universitätsklinik MünsterCode postal vérifiéMünster, Germany· Pas encore en recrutement
Questions fréquentes
What is 'extrahepatic cholangiocarcinoma'?
It's a type of cancer that starts in the bile ducts outside the liver.
What does 'unresectable' mean?
It means the cancer can't be fully removed with surgery.
What is ID-RFA?
It's a treatment that uses heat inside the bile ducts to destroy cancer cells and clear blockages.
What is Durvalumab?
It's a type of immunotherapy that helps your body's immune system fight cancer.
Est-ce un nouveau traitement ?
This study combines existing treatments in a new way to see if they work better together.
Comment en savoir plus
Christoph Roderburg, Prof. Dr.
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.